419 related articles for article (PubMed ID: 28870777)
1. Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34
Scordo M; Shah GL; Kosuri S; Herrera DA; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Avecilla ST; Meagher RC; Carlow DC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Tamari R; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2018 Jan; 24(1):133-141. PubMed ID: 28870777
[TBL] [Abstract][Full Text] [Related]
2. Impact of Toxicity on Survival for Older Adult Patients after CD34
Shah GL; Scordo M; Kosuri S; Herrera DA; Cho C; Devlin SM; Borrill T; Carlow DC; Avecilla ST; Meagher RC; O'Reilly RJ; Jakubowski AA; Papadopoulos EB; Koehne G; Gyurkocza B; Castro-Malaspina H; Shaffer BC; Perales MA; Giralt SA; Tamari R
Biol Blood Marrow Transplant; 2018 Jan; 24(1):142-149. PubMed ID: 28951193
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34
Kosuri S; Adrianzen Herrera D; Scordo M; Shah GL; Cho C; Devlin SM; Maloy MA; Nieves J; Borrill T; Carlow DC; Avecilla ST; Meagher RC; O'Reilly RJ; Papadopoulos EB; Jakubowski AA; Koehne G; Gyurkocza B; Castro-Malaspina H; Shaffer BC; Tamari R; Giralt SA; Perales MA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):2004-2011. PubMed ID: 28733264
[TBL] [Abstract][Full Text] [Related]
4. Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
Rondon-Clavo C; Scordo M; Hilden P; Shah GL; Cho C; Maloy MA; Papadopoulos EB; Jakubowski AA; O'Reilly RJ; Gyurkocza B; Castro-Malaspina H; Tamari R; Shaffer BC; Perales MA; Jaimes EA; Giralt SA
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2517-2522. PubMed ID: 30055353
[TBL] [Abstract][Full Text] [Related]
5. Pretransplantation Plasma ST2 Level as a Prognostic Biomarker of 1-Year Nonrelapse Mortality in Allogeneic Hematopoietic Cell Transplantation.
Gjærde LK; Ostrowski SR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
Transplant Cell Ther; 2023 Feb; 29(2):97.e1-97.e6. PubMed ID: 36375798
[TBL] [Abstract][Full Text] [Related]
6. Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34
Scordo M; Bhatt V; Hilden P; Smith M; Thoren K; Cho C; Shah GL; Maloy MA; Papadopoulos EB; Jakubowski AA; Avecilla ST; O'Reilly RJ; Castro-Malaspina H; Tamari R; Shaffer BC; Boelens JJ; Perales MA; Giralt SA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1526-1535. PubMed ID: 30831208
[TBL] [Abstract][Full Text] [Related]
7. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
8. Long-term prognosis for 1-year relapse-free survivors of CD34+ cell-selected allogeneic hematopoietic stem cell transplantation: a landmark analysis.
Cho C; Hsu M; Barba P; Maloy MA; Avecilla ST; Barker JN; Castro-Malaspina H; Giralt SA; Jakubowski AA; Koehne G; Meagher RC; O'Reilly RJ; Papadopoulos EB; Ponce DM; Tamari R; van den Brink MRM; Young JW; Devlin SM; Perales MA
Bone Marrow Transplant; 2017 Dec; 52(12):1629-1636. PubMed ID: 28991247
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
12. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
13. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
14. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
15. Dynamic EASIX scores closely predict nonrelapse mortality after allogeneic hematopoietic cell transplantation.
Nawas MT; Sanchez-Escamilla M; Devlin SM; Maloy MA; Ruiz JD; Sauter CS; Giralt SA; Perales MA; Scordo M
Blood Adv; 2022 Nov; 6(22):5898-5907. PubMed ID: 35977079
[TBL] [Abstract][Full Text] [Related]
16. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.
Baron F; Storb R; Storer BE; Maris MB; Niederwieser D; Shizuru JA; Chauncey TR; Bruno B; Forman SJ; McSweeney PA; Maziarz RT; Pulsipher MA; Agura ED; Wade J; Sorror M; Maloney DG; Sandmaier BM
J Clin Oncol; 2006 Sep; 24(25):4150-7. PubMed ID: 16896000
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
[TBL] [Abstract][Full Text] [Related]
19. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
20. Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.
Scordo M; Hsu M; Jakubowski AA; Shah GL; Cho C; Maloy MA; Avecilla ST; Papadopoulos EB; Gyurkocza B; Castro-Malaspina H; Tamari R; O'Reilly RJ; Perales MA; Giralt SA; Shaffer BC
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1136-1141. PubMed ID: 30625387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
